secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2026-03-24T23:59:59+00:00
Accession:  0001404644-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports FY2025 net loss $90.4M, cash $269M; NGN-401 dosing on track
-----------------------------------------------------------------------------

- Net loss $90.4M in FY2025 vs $75.1M in FY2024; cash $269M funds through Q1 2028.
- 100% enrolled in Embolden registrational trial for Rett syndrome; >50% dosed; on track to complete dosing Q2 2026.
- NGN-401 generally well-tolerated at 1E15 vg dose, no HLH cases; FDA Breakthrough Therapy designation granted.
- R&D expenses $75.0M up from $60.9M; G&A $28.3M up from $22.6M.
- Key milestones: interim Phase 1/2 data mid-2026, PPQ campaign mid-2026, BLA submission.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/0001404644-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/ngne-20260324.htm
  HTML page:      https://secwatch.observer/filing/0001404644-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer